Gritstone Oncology, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Emeryville CA United States (2015)

Organization Overview

First Clinical Trial
2018
NCT03639714
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Gritstone bio, Inc. | Gritstone Oncology | Gritstone Oncology, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Carcinoma, Transitional Cell (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 17